E-Therapeutics (ETXPF, $0.19) was a top loser over the last three months, falling -2 to $0.19 per share. A.I.dvisor analyzed 972 stocks in the Biotechnology Industry for the 3-month period ending March 24, 2023, and found that of them (4) exhibited an Uptrend while of them (5) demonstrated a Downtrend.